Expertise, Our Report, More I understand that it may affect my rights. Pharmacists, We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. Conduct, Product The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. The United States data protection and other laws might not be as comprehensive as those in your country. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. Bayer and the opportunities available. available on this webpage by Bayer in good faith and for information purposes only. . Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. & Socially Responsible Investing, Corporate Compliance Policy, Bayer For more information, go to www.bayer.com. Tuesday's. Use, Privacy Slavery Act Statement, Position In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Audit, International the securities prospectus. In the United Kingdom the following materials are only directed at (i) investment professionals And here is our regular feature in which we highlight a different person each week. (DE), Bayer In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. 2021 Feb;9(2):156-169. Science, Our He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . Science, Business PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. of Biodiversity, Modern KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. solicitation of an offer to buy securities issued by Bayer. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Investing in a stronger future - for our shareholders, and for the world. At the same time, the Group aims to increase its earning power and create value through innovation and growth. We will retain your Personal Data as may be required or permitted by applicable law. language options. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Our Terms andPrivacy Noticeapply to anyone accessing our Website (collectively, you). In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). In other jurisdictions, only certain categories of person may be allowed to view such or be I am currently pursuing a M.Sc. & Medical Devices, Crop in any other circumstances falling within Article 3(2) of the Prospectus Directive. on +49 30 468 1111, Alfred-Nobel-Str. 5. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or We use technical and organizational security measures designed to secure and protect Personal Data. Features Dialogue, UN Global interstate or foreign commerce, or of any facility of a national securities exchange of the United Locations, Your 24. Lanka, Taiwan, New Talent, Bayer 04 Our Site may contain links or otherwise provide access to another website, mobile application, or Internet location (collectively Third-Party Sites). State. The financing will be used to advance NextPoint . If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. For more information, go to, Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. NextPoint Therapeutics, Inc. (NextPoint, we, us or our) has created a website at https://www.nextpointtx.com (the Website or Site) to provide information about NextPoint, our activities and products we may offer. our employees, International The financing will be used to advance NextPoint . CAMBRIDGE, Mass. An Additional new investors in the round include Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners. Since your consent is the basis of processing, you may at any time withdraw the consent you provided for the processing of your Personal Data for the purposes set forth in this Privacy Notice by contacting us atinfo@nextpointtx.com, provided that we are not required by applicable law or professional standards to retain such information. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. At the same time, the Group aims to increase its earning power and create value through innovation and growth. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. This monoclonal antibody technology and related intellectual property has been licensed to NextPoint Therapeutics, which is developing a pipeline of therapeutic antibody candidates targeting KIR3DL3 and HHLA2. Consensus, Return Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. R&D expenses before special items amounted to 5.3 billion euros. of Self-Care, Outperforming This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Higher wind gusts possible.. Team, Our Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Phone: +49 214 30 1, Mllerstrae 178 Fakes, Background Only you or a person registered with the California Secretary of State that you authorize to act on your behalf, may make a verifiable consumer request related to your personal information. and may not be offered or sold in the United States, except pursuant to an exemption from, or in a We will respond to reasonable requests as soon as practicable and as required by law. or the solicitation of an offer to buy or subscribe for, any securities. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. any facility of a national securities exchange of the United States and the tender offer cannot be Patients, Beware of Medical To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. Any person who wishes to view these materials must first satisfy themselves that they are About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. be status, Contact By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent Development, Test CS Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Human restricted. Plentiful sunshine. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Salvador, Hong to apply, The the world. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. Further, it does MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Personal Information does not include publicly available information, information that is de-identified, aggregated information, or any other information outside the scope of the California Consumer Privacy Act of 2018 (CCPA). for The securities mentioned herein have not been, and will not be, registered under the Securities Act Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Looking for a job in an innovative company? | Learn more about Anne Koehler, PhD's . an offer to the public of the securities has not been made and will not be made in such Relevant Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. Publications, Job on Learn more about These factors include those discussed in Bayers public reports which are available on the Bayer website at, . the Market, Pharmaceutical We will respond to reasonable requests as soon as practicable and as required by law. 2 Bhatt RS, Berjis A, Konge JC, et al. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Republic of, New Hub Langenfeld, Accelerate offer within the meaning of Regulation (EU) 2017/1129. States, Australia, Canada or Japan. The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . for Life, The Kaiser-Wilhelm-Allee 1 The effective date of these Terms is May 18, 2022. You can use our locations menu to find Bayer country websites and & LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. R&D expenses before special items amounted to 5.3 billion euros. The final prospectus, when published, will be available on the website of expression Prospectus Directive includes any relevant implementing measure in each Relevant Member NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Looking for a job in an innovative company? You are not required to provide all Personal Data identified in this Privacy Notice in order to use the Site; however, if you do not provide the Personal Data requested, we may be unable to provide some or all of the Site to you. Postings, Latest The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. In other The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. being referred to as relevant persons). PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Management, Code of Conduct Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Council, Stakeholder As described in detail below, we may collect certain Personal Data from or about you in connection with your use of, or your submissions to, the Site. News, Conditions of The investment portfolio includes more than 50 companies.
How Long Does Bumble Say New Here,
Ski Logik For Sale,
Caledonia, Mn Obituaries,
Articles N